诺和诺德阿尔茨海默症药物试验失败，股价暴跌至2021年来最低。 高风险试验宣告失败 阿尔茨海默症以认知功能严重衰退、记忆丧失和性格改变为特征，是药物开发领域公认的难题。诺和诺德此前一直将这些试验描述为高风险项目。 诺和诺德宣布，公司的Ozempic口服版本在两项大型临床试验中未能减缓阿尔茨海默症进展，这一被视为长远投资的尝试宣告失败。基于认知评估结 果，服用该药物的患者并未出现显著好转。该公司已决定终止原定的一年期研究延长计划。 当地时间周一， 诺和诺德宣布，公司的Ozempic口服版本在两项大型临床试验中未能减缓阿尔茨海默症进展，这一被视为长远投资的尝试宣告失败。 基于认知评估结果，服用该药物的患者并未出现显著好转。 消息公布后，诺和诺德股价在哥本哈根交易中暴跌多达12.4%，触及2021年7月以来最低水平。 该公司已决定终止原定的一年期研究延长计划。 今年 以来，该股累计跌幅已超过一半，投资者对诺和诺德在肥胖症治疗这一蓬勃发展市场中的长期竞争力表示担忧。 竞争对手礼来公司股价在美股盘前交易中也出现下跌，而专注于阿尔茨海默症药物开发的Biogen股价则上涨6.7%。摩根士丹利分析师此前估计，如果 试验成功， ...

Core Viewpoint - Novo Nordisk's attempt to develop an oral version of Ozempic for Alzheimer's disease has failed in two large clinical trials, leading to a significant drop in its stock price and concerns about its long-term competitiveness in the obesity treatment market [1][5]. Group 1: Clinical Trial Results - The clinical trials did not show significant improvement in cognitive assessments for patients taking the drug, leading to the termination of a planned one-year extension study [1]. - The trials tracked over 3,500 patients with mild Alzheimer's disease, and while some physiological indicators showed improvement, it did not translate into a significant slowdown in disease progression [5]. Group 2: Market Reaction - Following the announcement, Novo Nordisk's stock price fell by as much as 12.4%, reaching its lowest level since July 2021, with a cumulative decline of over 50% this year [1][5]. - Competitor Eli Lilly's stock also dropped in pre-market trading, while Biogen, focused on Alzheimer's drug development, saw a 6.7% increase in its stock price [4]. Group 3: Financial Implications - Morgan Stanley analysts estimated that if the trials had been successful, the drug could have generated up to $5 billion in annual revenue for Novo Nordisk [4]. - The probability of success for the trials was estimated at 25%, with a failure probability of 75%, indicating the high-risk nature of the project [5].